SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
226 hedge funds and large institutions have $2.59B invested in SpringWorks Therapeutics in 2024 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 90 increasing their positions, 62 reducing their positions, and 22 closing their positions.
82% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 22
45% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 62
8% more funds holding
Funds holding: 209 → 226 (+17)
4.61% more ownership
Funds ownership: 104.16% → 108.77% (+4.6%)
11% less capital invested
Capital invested by funds: $2.91B → $2.59B (-$318M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
51% less call options, than puts
Call options by funds: $4.46M | Put options by funds: $9.02M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$45.8M |
| 2 |
Morgan Stanley
New York
|
+$41.6M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$18.7M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
+$17.4M |
| 5 |
CCM
Cutter Capital Management
New York
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$49.5M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$37.5M |
| 3 |
PA
Perceptive Advisors
New York
|
-$35.9M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$13.9M |
| 5 |
O
OrbiMed
New York
|
-$11.8M |
SWTX Hedge Fund Activity: Q3 2024 in Review
226 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q3 2024, worth a combined $2.59B — down 11% from $2.91B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SWTX positions and 22 closed out — a net gain of 18 holders — while 90 added to existing stakes and 62 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $45.8M. The largest seller was Artal Group, exiting entirely with an estimated $49.5M sold.
- 226 institutional investors held SpringWorks Therapeutics (SWTX) as of Q3 2024, up from 209 in Q2 2024.
- Funds reported $2.59B of SpringWorks Therapeutics stock for Q3 2024, down 11% quarter-over-quarter.
- 40 funds opened new SpringWorks Therapeutics positions in Q3 2024 and 22 closed out, a net change of +18 holders.
- The largest SpringWorks Therapeutics buyer in Q3 2024 was Capital International Investors, an estimated $45.8M added.
- The largest SpringWorks Therapeutics seller in Q3 2024 was Artal Group, an estimated $49.5M sold.
Based on aggregated 13F filings for Q3 2024.